340 related articles for article (PubMed ID: 25418426)
21. Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy.
Harbo T; Andersen H; Jakobsen J
Neurology; 2010 Oct; 75(15):1377-80. PubMed ID: 20938030
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy.
Gorson KC; Ropper AH; Weinberg DH; Weinstein R
Arch Neurol; 2002 May; 59(5):766-72. PubMed ID: 12020258
[TBL] [Abstract][Full Text] [Related]
23. Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins.
Ritter C; Bobylev I; Lehmann HC
J Neuroinflammation; 2015 Aug; 12():148. PubMed ID: 26268846
[TBL] [Abstract][Full Text] [Related]
24. Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens?
Rajabally YA; Wong SL; Kearney DA
J Neurol; 2013 Aug; 260(8):2052-6. PubMed ID: 23645220
[TBL] [Abstract][Full Text] [Related]
25. A new treatment regimen with high-dose and fractioned immunoglobulin in a special subgroup of severe and dependent CIDP patients.
Debs R; Reach P; Cret C; Demeret S; Saheb S; Maisonobe T; Viala K
Int J Neurosci; 2017 Oct; 127(10):864-872. PubMed ID: 27918219
[TBL] [Abstract][Full Text] [Related]
26. Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina.
Bezrodnik L; Gómez Raccio A; Belardinelli G; Regairaz L; Díaz Ballve D; Seminario G; Moreira I; Riganti C; Cantisano C; Díaz H; Di Giovanni D
J Clin Immunol; 2013 Oct; 33(7):1216-22. PubMed ID: 23846854
[TBL] [Abstract][Full Text] [Related]
27. Intravenous immunoglobulin treatment in multifocal motor neuropathy and other chronic immune-mediated neuropathies.
Comi G; Nemni R; Amadio S; Galardi G; Leocani L
Mult Scler; 1997 Apr; 3(2):93-7. PubMed ID: 9291161
[TBL] [Abstract][Full Text] [Related]
28. Intravenous immunoglobulin for treatment of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy in France: are daily practices in accordance with guidelines?
Rosier C; Graveline N; Lacour A; Antoine JC; Camdessanché JP
Eur J Neurol; 2019 Apr; 26(4):575-580. PubMed ID: 30326184
[TBL] [Abstract][Full Text] [Related]
29. Current treatments of chronic immune-mediated demyelinating polyneuropathies.
Brannagan TH
Muscle Nerve; 2009 May; 39(5):563-78. PubMed ID: 19301378
[TBL] [Abstract][Full Text] [Related]
30. Changes of Serum IgG Dimer Levels after Treatment with IVIg in Guillain-Barré Syndrome.
Svačina MKR; Röth P; Bobylev I; Sprenger A; Zhang G; Sheikh KA; Lehmann HC
J Neuroimmune Pharmacol; 2019 Dec; 14(4):642-648. PubMed ID: 31515689
[TBL] [Abstract][Full Text] [Related]
31. Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy.
Kuitwaard K; van Doorn PA; Vermeulen M; van den Berg LH; Brusse E; van der Kooi AJ; van der Pol WL; van Schaik IN; Notermans N; Tio-Gillen AP; van Rijs W; van Gelder T; Jacobs BC
J Neurol Neurosurg Psychiatry; 2013 Aug; 84(8):859-61. PubMed ID: 23538070
[TBL] [Abstract][Full Text] [Related]
32. Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review.
Danieli MG; Gelardi C; Pedini V; Moretti R; Gabrielli A; Logullo F
Autoimmun Rev; 2014 Dec; 13(12):1182-8. PubMed ID: 25172241
[TBL] [Abstract][Full Text] [Related]
33. What is the contents of the magic draft IVIg?
Seite JF; Shoenfeld Y; Youinou P; Hillion S
Autoimmun Rev; 2008 Jun; 7(6):435-9. PubMed ID: 18558358
[TBL] [Abstract][Full Text] [Related]
34. [Antiganglioside antibodies: when, which and for what].
Gallardo E; Rojas-García R; Belvís R; Serrano-Munuera C; Ortiz E; Ortiz N; Grau J; Illa I
Neurologia; 2001; 16(7):293-7. PubMed ID: 11485721
[TBL] [Abstract][Full Text] [Related]
35. A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies.
Lunn MP; Ellis L; Hadden RD; Rajabally YA; Winer JB; Reilly MM
J Peripher Nerv Syst; 2016 Mar; 21(1):33-7. PubMed ID: 26757367
[TBL] [Abstract][Full Text] [Related]
36. Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin.
Vu T; Anthony N; Alsina R; Harvey B; Schleutker A; Farias J; Dang S; Suresh N; Gooch C
Muscle Nerve; 2021 Sep; 64(3):351-357. PubMed ID: 34076265
[TBL] [Abstract][Full Text] [Related]
37. Intravenous IgG Reduces Pathogenic Autoantibodies, Serum IL-6 Levels, and Disease Severity in Experimental Bullous Pemphigoid Models.
Sasaoka T; Ujiie H; Nishie W; Iwata H; Ishikawa M; Higashino H; Natsuga K; Shinkuma S; Shimizu H
J Invest Dermatol; 2018 Jun; 138(6):1260-1267. PubMed ID: 29391250
[TBL] [Abstract][Full Text] [Related]
38. Anti-GM1 antibodies in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) treated with intravenous immunoglobulin (IVIg).
van Schaik IN; Vermeulen M; van Doorn PA; Brand A
J Neuroimmunol; 1994 Oct; 54(1-2):109-15. PubMed ID: 7929799
[TBL] [Abstract][Full Text] [Related]
39. Update on therapy of chronic immune-mediated neuropathies.
Briani C; Cocito D; Campagnolo M; Doneddu PE; Nobile-Orazio E
Neurol Sci; 2022 Dec; 43(Suppl 2):605-614. PubMed ID: 33452933
[TBL] [Abstract][Full Text] [Related]
40. Comparisons in fluctuation of muscle strength and function in patients with immune-mediated neuropathy treated with intravenous versus subcutaneous immunoglobulin.
Christiansen I; Markvardsen LH; Jakobsen J
Muscle Nerve; 2018 Apr; 57(4):610-614. PubMed ID: 28881389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
